Advertisement

Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer

  • Sung Yong Oh
  • Suee Lee
  • Seok Jae Huh
  • Jeeyun Lee
  • Seung Tae Kim
  • Se Hoon Park
  • Ho Yeong Lim
  • Won Ki Kang
  • Byung Woog Kang
  • Jong Gwang Kim
  • Hyo Jin Lee
  • Jung Hoon Kim
  • Jung Hun Kang
  • HoUng Kim
Original Article
  • 57 Downloads

Abstract

Purpose

To investigate the safety and efficacy of 30-min maintenance infusions of trastuzumab in advanced gastric cancer positive for human epidermal growth factor receptor 2 (HER2).

Methods

This was a retrospective study conducted across five Korean hospitals in patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma treated with first-line, 3-weekly trastuzumab plus chemotherapy. The first dose of trastuzumab (8 mg/kg) was administered as a 90-min infusion, with all subsequent maintenance infusions (6 mg/kg) given over 30 min. The primary aim was to investigate infusion-related reactions and cardiac events with 30-min infusions of trastuzumab. Objective response rate, progression-free survival, and overall survival were secondary endpoints.

Results

The study included 128 patients (efficacy population), of whom 123 received both induction and maintenance infusions and formed the safety population. The median age was 63 years; 80% were presenting for the first time with metastatic disease, and 94% were treated with trastuzumab plus capecitabine/cisplatin. Infusion-related reactions were observed in 32 of 123 patients (26%). There were no cardiac events. The most frequent adverse events were anorexia and nausea, followed by vomiting, fatigue, mucositis, sensory neuropathy, and hand–foot syndrome. Most events were grade 1–2 and were manageable. No patient discontinued study treatment due to adverse events. The objective response rate was 63%, and included 6 complete responses.

Conclusions

Trastuzumab 30-min maintenance infusions were well tolerated with a good safety profile, and resulted in sustained efficacy in patients with HER2-positive advanced gastric cancer.

Keywords

30-min infusion Trastuzumab Gastric cancer Chemotherapy Rapid infusion HER2 

Notes

Acknowledgements

Medical writing support (including development of a draft outline and subsequent drafts in consultation with the authors, assembling tables and figures, collating author comments, copyediting, fact checking and referencing) was provided by Rick Flemming PhD, CMPP at Aspire Scientific Limited (Bollington, UK) and was funded by CELLTRION Healthcare Co., Ltd. (Incheon, Republic of Korea). We thank all patients involved in this study.

Author contributions

SYO and JGK were involved in study conception and design, acquisition of data, and analysis/interpretation of data. SJH, BWK, HJL, and JHK were involved in acquisition of data, and analysis/interpretation of data. JL, SL, STK, SHP, JHK, HYL, and WKK were involved in acquisition of data. HK was involved in analysis and interpretation of data. All authors had full access to all the data in the study, reviewed drafts of the manuscript, approved the final version, had final responsibility for the decision to submit for publication, and agree to be accountable for the work.

Funding

This work was supported by the Dong-A University Research Fund.

Compliance with ethical standards

Conflict of interest

HoUng Kim is an employee of CELLTRION Healthcare Co., Ltd. All other authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

References

  1. 1.
    World Health Organization. International Agency for Research on Cancer (2012) GLOBOCAN 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 14 Mar 2018
  2. 2.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697.  https://doi.org/10.1016/s0140-6736(10)61121-x CrossRefGoogle Scholar
  3. 3.
    Cabebe EC (2018) Gastric cancer. Practice essentials. Medscape, LLC. https://emedicine.medscape.com/article/278744-overview. Accessed 15 Mar 2018
  4. 4.
    Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E, Ciardiello F, De Vita F (2014) Treatment of gastric cancer. World J Gastroenterol 20(7):1635–1649.  https://doi.org/10.3748/wjg.v20.i7.1635 CrossRefGoogle Scholar
  5. 5.
    den Hoed CM, Kuipers EJ (2016) Gastric cancer: how can we reduce the incidence of this disease? Curr Gastroenterol Rep 18(7):34.  https://doi.org/10.1007/s11894-016-0506-0 CrossRefGoogle Scholar
  6. 6.
    Lee JS, Kim SH, Im SA, Kim MA, Han JK (2017) Human epidermal growth factor receptor 2 expression in unresectable gastric cancers: relationship with CT characteristics. Korean J Radiol 18(5):809–820.  https://doi.org/10.3348/kjr.2017.18.5.809 CrossRefGoogle Scholar
  7. 7.
    Fock KM (2014) Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther 40(3):250–260.  https://doi.org/10.1111/apt.12814 CrossRefGoogle Scholar
  8. 8.
    Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH, Community of Population-Based Regional Cancer Registries (2017) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat 49(2):292–305.  https://doi.org/10.4143/crt.2017.118 CrossRefGoogle Scholar
  9. 9.
    Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19(9):1523–1529.  https://doi.org/10.1093/annonc/mdn169 CrossRefGoogle Scholar
  10. 10.
    Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Ruschoff J, Henkel T (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52(7):797–805.  https://doi.org/10.1111/j.1365-2559.2008.03028.x CrossRefGoogle Scholar
  11. 11.
    Liu X, Xu P, Qiu H, Liu J, Chen S, Xu D, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Sun X (2016) Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer. Onco Targets Ther 9:949–958.  https://doi.org/10.2147/OTT.S100979 CrossRefGoogle Scholar
  12. 12.
    Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9):2639–2648.  https://doi.org/10.1200/jco.1999.17.9.2639 CrossRefGoogle Scholar
  13. 13.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672.  https://doi.org/10.1056/NEJMoa052306 CrossRefGoogle Scholar
  14. 14.
    Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684.  https://doi.org/10.1056/NEJMoa052122 CrossRefGoogle Scholar
  15. 15.
    Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3):719–726.  https://doi.org/10.1200/jco.2002.20.3.719 CrossRefGoogle Scholar
  16. 16.
    Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792.  https://doi.org/10.1056/nejm200103153441101 CrossRefGoogle Scholar
  17. 17.
    Genentech Inc (2017) Highlights of prescribing information. Herceptin® (trastuzumab) for injection, for intravenous use. https://www.gene.com/download/pdf/herceptin_prescribing.pdf. Accessed 12 June 2018
  18. 18.
    Lenz HJ (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12(5):601–609.  https://doi.org/10.1634/theoncologist.12-5-601 CrossRefGoogle Scholar
  19. 19.
    Abe H, Mori T, Kawai Y, Tomida K, Yamazaki K, Kubota Y, Umeda T, Tani T (2013) Safety assessment of intravenous administration of trastuzumab in 100 ml saline for the treatment of HER2-positive breast cancer patients. Asian Pac J Cancer Prev 14(8):4843–4846Google Scholar
  20. 20.
    Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23(10):2162–2171.  https://doi.org/10.1200/jco.2005.01.014 CrossRefGoogle Scholar
  21. 21.
    Cook-Bruns N (2001) Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61(Suppl 2):58–66.  https://doi.org/10.1159/000055403 CrossRefPubMedGoogle Scholar
  22. 22.
    Abe H, Umeda T, Kawai Y, Tanaka M, Mori T, Cho H, Kubota Y, Mekata E, Kurumi Y, Tani T (2010) Adjuvant trastuzumab can be infused safely over 30 minutes. Gan To Kagaku Ryoho 37(10):1887–1891Google Scholar
  23. 23.
    Ring A, Simcock R, Mitra S, Bloomfield D, King J, Simpson S, Sadler G, Webb A (2008) Infusion of trastuzumab maintenance doses over 30 minutes. Ann Oncol 19(8):1509–1510.  https://doi.org/10.1093/annonc/mdn390 CrossRefGoogle Scholar
  24. 24.
    Papouchado BG, Myles J, Lloyd RV, Stoler M, Oliveira AM, Downs-Kelly E, Morey A, Bilous M, Nagle R, Prescott N, Wang L, Dragovich L, McElhinny A, Garcia CF, Ranger-Moore J, Free H, Powell W, Loftus M, Pettay J, Gaire F, Roberts C, Dietel M, Roche P, Grogan T, Tubbs R (2010) Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol 34(6):767–776.  https://doi.org/10.1097/PAS.0b013e3181d96231 CrossRefGoogle Scholar
  25. 25.
    Dietel M, Ellis IO, Hofler H, Kreipe H, Moch H, Dankof A, Kolble K, Kristiansen G (2007) Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 451(1):19–25.  https://doi.org/10.1007/s00428-007-0424-5 CrossRefGoogle Scholar
  26. 26.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247.  https://doi.org/10.1016/j.ejca.2008.10.026 CrossRefGoogle Scholar
  27. 27.
    Tobinai K, Klein C, Oya N, Fingerle-Rowson G (2017) A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-Cell malignancies. Adv Ther 34(2):324–356.  https://doi.org/10.1007/s12325-016-0451-1 CrossRefGoogle Scholar
  28. 28.
    Pritchard CH, Greenwald MW, Kremer JM, Gaylis NB, Rigby W, Zlotnick S, Chung C, Jaber B, Reiss W (2014) Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study. BMC Musculoskelet Disord 15:177.  https://doi.org/10.1186/1471-2474-15-177 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Sung Yong Oh
    • 1
  • Suee Lee
    • 1
  • Seok Jae Huh
    • 1
  • Jeeyun Lee
    • 2
  • Seung Tae Kim
    • 2
  • Se Hoon Park
    • 2
  • Ho Yeong Lim
    • 2
  • Won Ki Kang
    • 2
  • Byung Woog Kang
    • 3
  • Jong Gwang Kim
    • 3
  • Hyo Jin Lee
    • 4
  • Jung Hoon Kim
    • 5
  • Jung Hun Kang
    • 5
  • HoUng Kim
    • 6
  1. 1.Department of Internal MedicineDong-A University College of MedicineBusanRepublic of Korea
  2. 2.Division of Hematology–Oncology, Department of MedicineSamsung Medical Center, Sungkyunkwan University School of MedicineSeoulRepublic of Korea
  3. 3.Department of Oncology/HematologyKyungpook National University Medical Center, Kyungpook National University School of MedicineDaeguRepublic of Korea
  4. 4.Division of Hematology–Oncology, Department of Internal MedicineChungnam National University College of MedicineDaejeonRepublic of Korea
  5. 5.Division of Hematology/Oncology, Department of Internal Medicine, School of MedicineGyeongsang National UniversityJinjuRepublic of Korea
  6. 6.CELLTRION Healthcare Co. LtdIncheonRepublic of Korea

Personalised recommendations